Development and dynamics of robust T-cell responses to CML under imatinib treatment

Blood

Volumn 111, Issue 11, 2008, Pages 5342-5349

  Chen, Christiane L U ^a   Maecker, Holden T ^b   Lee, Peter P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BD BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN; RNA; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKEMIA; LEUKEMIA CELL; LYMPHOCYTE CLONE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; CELL CLONE; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLONE CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45749101780     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-128397     Document Type: Article

References (36)

1. Sawyers CL. Ghronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
2. Lee SJ. Chronic myelogenous leukaemia. Br J Haematol. 2000;111:993-1009.
3. Angstreich GR, Smith BD, Jones RJ. Treatment options tor chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. Curr Opin Oncol. 2004;16:95-99.
4. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432.
5. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691-1701.
6. Mohty M, Jourdan E, Mami NB, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood. 2004;103: 4666-4668.
7. Sato N, Narita M, Takahashi M, et al. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol. 2003;21:67-75.
8. Gannage M. Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CDS T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005;174:8210-8218.
9. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000:6:1018-1023.
10. Dodi IA, Van Rhee F, Forde HC, et al. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy. 2002;4:353-363.
11. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8+ memory T cells. J Exp Med. 1997;186: 859-865.
12. Nomura LE. Walker JM, Maecker HT. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells. Cytometry. 2000:40:60-68.
13. Rubio V. Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003;9:1377-1382.
14. Stuge TB, Holmes SP, Saharan S, et al. Diversity and recognition efficiency of T-cell responses to cancer. PLoS Med (http://medicine. plosjournals.org/). 2004;1:e28.
15. Obata F, Tsunoda-lizuka M. Analysis of the T-cell receptors utilized for allogeneic HLA-DR recognition: comparison of different responder-cell donors possessing an identical HLA-DR allele. Scand J Immunol. 1998;48:364-370.
16. Prabhakar U, Eirikis E, Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J Immunol Methods. 2002;260:207-218.
17. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med. 2005:11:1113-1117.
18. Wang H, Cheng F, Cuenca A, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 2005;105:1135-1143.
19. Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol Med. 2005;11:397-402.
20. Brauer KM, Werth D, von Schwarzenberg K, et al. BCR-ABL activity is critical tor the immunogenicity of chronic myelogenous leukemia cells. Cancer Res. 2007;67:5489-5497.
21. Scheich F. Duyster J. Peschel C, Bernhard H. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood. 2007;110:2556-2560.
22. Appel S, BoehmLer AM, Grunebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood. 2004;103:538-544.
23. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657-662.
24. Kao JY, Zhang M, Chen CM, Pierzchala A, Chen JJ. Aberrant T helper cell response in tumor-bearing mice limits the efficacy of dendritic cell vaccine. Immunol Lett. 2006;105:16-25.
25. Zorn E, Wang KS, Hochberg EP, et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002;8:2052-2060.
26. Cathcart K, Pinilla-lbarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103:1037-1042.
27. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 2005;23:413-419.
28. Gerloni M. Zanetti M. CD4T cells in tumor immunity. Springer Semin Immunopathol. 2005;27:37-48.
29. Assudani DP, Horton RB, Mathieu MG, McArdle SE. Rees RC The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Gancer Immunol Immunother. 2007;56: 70-80.
30. Mumberg D, Monach PA, Wanderling S, et al. CD4(+) T cells eliminate MHC class ll-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A. 1999;96: 8633-8638.
31. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Gancer Res. 2000;6:1671-1677.
32. De Rosa SC, Lu FX, Yu J, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol. 2004;173:5372-5380.
33. Uberti JP, Ayash L Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methyl-prednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11:680-687.
34. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother. 2006; 55:734-743.
35. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35-53.
36. Scheibenbogen C, Letsch A, Thiel E, et al. CDS T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132-2137.